Product Information : Genetically modified drug for mucopolysaccharidosis Type VI
We provide information
about BioMarin’s products for healthcare professionals.
Product Information
Genetically modified drug for mucopolysaccharidosis Type VI:
NAGLAZYME® Intravenous Solution 5mg
![NAGLAZYME® Intravenous Solution 5mg](https://www.bmrn.co.jp/cms/wp-content/themes/biomarin/img/physicians/product02_sp.png)
NAGLAZYME® (galsulfase) is an enzyme replacement therapy for the treatment of mucopolysaccharidosis Ⅵ (Maroteaux-Lamy Syndrome).
![NAGLAZYME® Intravenous Solution 5mg](https://www.bmrn.co.jp/cms/wp-content/themes/biomarin/img/physicians/product02_pc.png)
Generic Name | Galsulfase (genetically modified) |
---|---|
Indication | Mucopolysaccharidosis Ⅵ |
Dosage and Administration | Usually, intravenously infuse 1 mg of galsulfase (genetically modified) per kg body weight at a time, once a week. |
Materials on Our Products
For more information on diseases and products, please refer to the following PDF documents.
Medical Reference
BioMarin Pharmaceutical Japan K.K. has established a medical information site " Medical Plus " For healthcare professionals .